Asset Details
Do you wish to reserve the book?
Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma
Do you wish to request the book?
Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma
2013
Overview
This randomized study showed that including autologous transplantation as part of primary treatment improved progression-free survival but not overall survival among high-intermediate-risk and high-risk patients with aggressive lymphoma.
Autologous stem-cell transplantation has long been known to improve both progression-free survival and overall survival among patients with diffuse, aggressive non-Hodgkin's lymphoma in second remission.
1
When it became possible to identify patients at diagnosis who have less than a 50% chance of sustained remission, as defined by the International Prognostic Index
2
(IPI) (see Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org), trials of up-front transplantation in this group were conducted. In the first trial, LNH-87, patients received full-course induction chemotherapy, regardless of their IPI risk category; those with a complete response were randomly . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Antibodies, Monoclonal, Murine-Derived - therapeutic use
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Biological and medical sciences
/ Cyclophosphamide - therapeutic use
/ Doxorubicin - therapeutic use
/ Female
/ Hematologic and hematopoietic diseases
/ Humans
/ Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
/ Lymphoma
/ Lymphoma, Non-Hodgkin - drug therapy
/ Lymphoma, Non-Hodgkin - mortality
/ Lymphoma, Non-Hodgkin - therapy
/ Male
/ Patients
